Somewhat of a landmark study with all contributing to the study and perhaps some answers will arise as for all to continue to exist in the market place this makes sense to search for clinical data that can be used. Perhaps genomics might enter the study here as well with additional information up front on administering Warfarin as well. BD 
The market for drug-coated stents has been shrinking partly due to worries about blood clots forming long after the devices are implanted to prop open the arteries around the heart. Now, all those companies fighting for market share are joining together to launch a great big study that aims to figure out the best way to reduce the risk of clots, the WSJ reports. Abbott, Medtronic, Boston Scientific and Johnson & Johnson will all participate in the $100 million, four-year, 20,000-patient project. The basic question they hope to answer: Should patients be on aggressive blood-thinning treatment for one year after receiving a stent, or should they stay on blood thinners for at least 2 1/2 years.
Related Reading:
Who's going to pay for the Warfarin Test - Personalized Medicine
FDA Clears Osmetech's Warfarin Sensitivity Test
For Sick Heart Patients, Bypass Surgery Beats Stents
Kaiser and Stanford get $3.89M to study heart disease with linked medical records - California
Health Blog : The Stent-Industrial Complex Comes Together For Safety Study
0 comments :
Post a Comment